Matsoukas, John
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Matsoukas, J. (John)
VIAF ID: 39551325 (Personal)
Permalink: http://viaf.org/viaf/39551325
Preferred Forms
-
200 _ |
‡a
Matsoukas
‡b
John
-
100 1 _ ‡a Matsoukas, J. ‡q (John)
-
100 1 _
‡a
Matsoukas, J.
‡q
(John)
-
100 1 0
‡a
Matsoukas, J.
‡q
(John)
-
100 1 _ ‡a Matsoukas, J. ‡q (John)
-
100 1 _
‡a
Matsoukas, John
-
100 1 _
‡a
Matsoukas, John
-
100 1 _
‡a
Matsoukas, John
-
100 1 _ ‡a Matsoukas, John
4xx's: Alternate Name Forms (4)
Works
| Title | Sources |
|---|---|
| Bioactive peptides in drug discovery and design medical aspects |
|
| A combined NMR and molecular dynamics simulation study to determine the conformational properties of agonists and antagonists against experimental autoimmune encephalomyelitis |
|
| Comparative conformational analysis studies between Losartan derivatives |
|
| Conformation and bioactivity. Design and discovery of novel antihypertensive drugs |
|
| Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3,5 side-chain bridges : Role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists |
|
| An efficient synthetic method and theoretical calculations of olmesartan methyl ether : study of biological function of AT1 antagonism |
|
| Interactions of the potent synthetic AT1 antagonist analog BV6 with membrane bilayers and mesoporous silicate matrices |
|
| A putative bioactive conformation for the altered peptide ligand of myelin basic protein and inhibitor of experimental autoimmune encephalomyelitis [Arg(91), Ala(96)] MBP(87-99) |
|
| Putative bioactive conformers of small molecules: a concerted approach using NMR spectroscopy and computational chemistry |
|
| Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers |
|
| Structure elucidation and conformational study of V8 : a novel synthetic non peptide AT1 antagonist |
|
